GM-CSF Inhalation to Improve Host Defense and Pulmonary Barrier Restoration (GI-HOPE). A Randomized, Double-blind, Parallel Group, Multicenter, Phase II Study

Trial Profile

GM-CSF Inhalation to Improve Host Defense and Pulmonary Barrier Restoration (GI-HOPE). A Randomized, Double-blind, Parallel Group, Multicenter, Phase II Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Molgramostim (Primary)
  • Indications Adult respiratory distress syndrome
  • Focus Therapeutic Use
  • Acronyms GI-HOPE
  • Sponsors Savara Pharmaceuticals; Serendex Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jan 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 07 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top